Drug intelligence / Profile preview

AFX-3921

Development stage: Preclinical
Lead developer: LEO Pharma
Modality: Small Molecules

Overview

AFX-3921 is a small molecule therapeutic candidate currently in preclinical development by Afecta Pharmaceuticals for the treatment of hidradenitis (likely hidradenitis suppurativa). As of the company's 2020 pipeline update, the asset was listed as being in the preclinical phase. Specific details regarding its molecular target, chemical structure, or mechanism of action have not been publicly disclosed by the sponsor. The drug is part of Afecta's broader portfolio focused on re-engineering existing compounds or developing novel small molecules for inflammatory and dermatological conditions.

Beyond the preview

Go deeper on AFX-3921.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AFX-3921.

Explore the full profile